Number of the records: 1  

A Novel Roscovitine Derivative Potently Induces G(1)-Phase Arrest in Platelet-Derived Growth Factor-BB-Activated Vascular Smooth Muscle Cells

  1. 1.
    0344007 - ÚEB 2011 RIV US eng J - Journal Article
    Sroka, I. M. - Heiss, E.H. - Havlíček, Libor - Totzke, F. - Aristei, Y. - Pechan, P. - Kubbutat, M.H.G. - Strnad, Miroslav - Dirsch, V.M.
    A Novel Roscovitine Derivative Potently Induces G(1)-Phase Arrest in Platelet-Derived Growth Factor-BB-Activated Vascular Smooth Muscle Cells.
    Molecular Pharmacology. Roč. 77, č. 2 (2010), s. 255-261. ISSN 0026-895X
    R&D Projects: GA ČR GA301/08/1649
    Grant - others:_(XE) LSHB-CT-2004-503467
    Institutional research plan: CEZ:AV0Z50380511
    Keywords : CYCLIN-DEPENDENT KINASES * DRUG-ELUTING STENTS * CYC202 R-ROSCOVITINE
    Subject RIV: FD - Oncology ; Hematology
    Impact factor: 4.725, year: 2010

    Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to the pathogenesis of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising candidates for an antirestenotic therapy. In this study, we pharmacologically characterize N-5-(2-aminocyclohexyl)-N-7-benzyl-3-isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine-5,7-di-amine (LGR1406), a novel derivative of the cyclin-dependent kinase (CDK) inhibitor roscovitine (ROSC), in PDGF-BB-activated VSMC. Cell proliferation was quantified measuring DNA synthesis via 5-bromo-2'-deoxyuridine incorporation. Analysis of cell cycle distribution was done by flow cytometry using propidium iodide-stained nuclei. Key regulators of the cell cycle and relevant signaling pathways were dissected by Western blot analyses. In addition, in vitro kinase assays and in silico studies regarding the pharmacokinetic profile of both compounds were performed.
    Permanent Link: http://hdl.handle.net/11104/0186345
    FileDownloadSizeCommentaryVersionAccess
    2010_Sroka_MOLECULAR PHARMACOLOGY_255.pdf82.1 MBOtheropen-access
     
Number of the records: 1